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Abstract 
Low Molecular Weight Protein Tyrosine Phosphatase (LMW-PTP) isoform 2 (IF2) has been 
found to be over expressed in many forms of aggressive cancer and has become a target for 
inhibition. Competitive inhibition of LMW-PTP IF2 by known inhibitor pyridoxal-5'-phosphate 
(PLP) shows a strong inhibition constant (Ki = 7.6 μM at pH 5.0); however, PLP is a cofactor for 
many other enzymes. In silico screening and in vitro testing identified NSC107022 (Ki = 10.8 ± 
1.0) from the National Cancer Institute's Diversity Set II as a lead compound for optimization as 
a LMW-PTP IF2 inhibitor. Utilizing NSC107022's galloyl group, compound libraries of 
aromatic alcohols and amines were connected (ester and amide linkages, respectively) and 
screened in silico. Twelve compounds, eight esters and four amides yielding top docking scores 
(most negative) were selected for synthesis and in vitro screening. 
 
Introduction 
Post-translation phosphorylation of protein Ser, Thr and Tyr residues is an important reversible 
modification that plays a central role in eukaryotic cellular activities such as cell growth, 
proliferation, differentiation, migration and gene expression.
1
 The phosphorylation and 
dephophorylation of tyrosine residues is under dynamic control of protein tyrosine kinases 
(PTKs) and protein tyrosine phosphatases (PTPs), respectively. The human genome codes for 
107 known PTPs which can be classified into four subgroups: classical pTyr specific, dual 
specificity, Cdc25 and low molecular weight protein tyrosine phosphatases (LMW-PTP).
2,3 
All 
PTPs share a common active site phosphate binding P-loop (CX5R(S/T)) and catalytic 
mechanism involving a crucial cysteine residue but differ greatly in tertiary structure, sequence 
and specificity.
2 
The LMW-PTP subgroup has recently emerged as a novel drug target due to 
their involvement in metabolic and tumor regulation.
1
 
 LMW-PTPs are 18 kDa enzymes with no particular tissue specificity belonging to class II 
cysteine based PTPs.
4
 Human LMW-PTP is active downstream in growth factor signaling 
pathways and is linked to cellular transformation and tumor onset.
2,3,5,6
 LMW-PTP mRNA and 
protein levels are shown to be highly increased in human breast, kidney, colon and bladder tumor 
samples.
7
 Moreover, overexpression of LMW-PTP causes neoplastic cellular transformation and 
cancer progression.
5 
Likewise, increased levels of LMW-PTP is characteristic of more aggressive 
cancer.
8,9 
 
 LMW-PTP gains its oncogenic potential through expression of the ephrin A2 (EphA2) 
receptor tyrosine kinase.
6
 The overexpression of EphA2 is linked to many types of aggressive 
and metastatic cancers. Dephosphorylated EphA2 promotes cellular migration and tumor onset. 
In cancer cells, overexpression of LMW-PTP is a crucial EphA2 regulator and in turn leads to 
high levels of dephosphorylated EphA2 which triggers neoplastic transformation of non-
transformed cells.
1,5
 Likewise, the action of LMW-PTP on EphA2 reduces its ability to 
dephosphorylate p190Rho-GAP which is critical for cell-matrix adhesion.
2
 The Rho family of 
GTPases are important regulators of cell migration and this weakened adhesion leads to greater 
cell motility and migration.
10  
The LMW-PTP family is found as four different isozymes: two active forms, isoform 1 
(also known as IFA, HCPTA or fast) and isoform 2 (also known as IFB, HCPTB or slow), and 
two catalytically inactive forms, IFC and SV3 (splicing variant 3). The two active isoforms are 
derived from alternative splicing of the same primary RNA transcript and differ only in sequence 
of residues 40-73.
3
 This section flanks the catalytic active site and determines ligand specificity 
and modulation for the isoforms. Thus, different cellular functions have been suggested for 
isoform 1 and 2.
11,12
 Recently, data has shown the isoforms have opposite roles in tumorgenesis, 
where isoform 1 is anti-oncogenic and isoform 2 is oncogenic.
13 
 
 
Fig. 1. Structures of PLP and NSC107022, respectively.  
 
 Few inhibitors for human LMW-PTP have been discovered due to its relatively recent 
discovery as a novel drug target. Pyridoxal 5’-phosphate (PLP, Fig 1) is a known inhibitor of 
LMW-PTP which displays tight binding (Ki=7.6 µM, pH 5).
14
 Unfortunately, PLP is a necessary 
cofactor for a plethora of enzymes and lacks the specificity required to inhibit LMW-PTP. 
Virtual screening of compound libraries has emerged as a useful technique to help increase the 
speed of identification of potential inhibitors for LMW-PTP.
4,9 
Seiler et al. utilized in silico 
docking methods to analyze the National Cancer Institute’s (NCI) Diversity Sets II and III and 
screened potential compounds in vitro. NSC107022 (Fig 1) of NCI Diversity Set II showed 
similar binding to that of PLP (10.8 ± 1.0 µM, pH 5.5)
4
 and was chosen for optimization. 
Utilizing the galloyl core of NSC107022 libraries of aryl alcohols and aromatic primary amines 
were coupled and docked in silico. Top molecules were subject to further docking then selected 
for synthesis and in vitro evaluation. 
 
Results and Discussion 
Compound libraries of aryl alcohols (approx. 3,000 molecules) and primary aromatic amines 
(approx. 3,500 molecules) obtained from Sigma-Aldrich were coupled to a galloyl base and 
docked into LMW-PTP IF2 in silico. The original screening process revealed ester linkages with 
a β-amino acid motif displayed the best docking scores, better than that of PLP shown in figure 
2. After further in silico docking seven β-amino acids were selected for synthesis. 3-Amino-3-(3-
methoxy-4-((3,4,5-trihydroxybenzoyl)oxy)phenyl)propanoic acid showed the best docking score 
(-10.401). Key interactions with LMW-PTP IF2 include hydrogen bonds of the galloyl hydroxyl 
groups with Trp49 along with π-π bonding with the same residue. The amino group of the 
molecule hydrogen bonded with Asp129 while the carboxyl group hydrogen bonded with Arg18 
through the carbonyl and Cys17 and Ile16 through the deprotonated oxygen (Fig. 7). These 
interactions are different from that of NSC107022 (Fig. 3) with only Asp129 and Arg18 being in 
common. This points to a different orientation in the active site; however, the immense amount 
of hydrogen bonding relates to the better docking score when compared to NSC107022 as seen 
in Table 1. The only β-amino acid chosen without additional functional groups off of the aryl 
ring was 3-amino-3-(3-((3,4,5-trihydroxybenzoyl)oxy)phenyl)propanoic acid (Fig. 5). This β-
amino acid was also only one of two that had a meta relationship to amino acid motif while the 
other five had a para relationship. In common with 3-amino-3-(3-methoxy-4-((3,4,5-
trihydroxybenzoyl)oxy)phenyl)propanoic acid this molecule had the same interactions through 
the amino acid group utilizing residues Asp129, Arg18, Cys17 and Ile16 in the same fashion for 
hydrogen bonding. It was interesting to note that all β-amino acids hydrogen bonded with the 
aforementioned residues. Also, π-π non-polar interactions were seen for all β-amino acids and 
Tyr131. These interactions may be important for tight binding to LMW-PTP IF2 suggested by 
their better docking scores than PLP and NSC107022. All of the β-amino acids entered the active 
site with amino acid motif with the galloyl group pointing out of the active site and can be seen 
docked in LMW-PTP IF2 with key interactions in figures 5-11.  
 The screening of primary aromatic amines utilizing an amide linkage with the galloyl 
base resulted in poorer docking scores than the esters, NSC107022 and PLP. While the docking 
scores for LMW-PTP IF2 were not better than PLP, the docking scores in LMW-PTP IF1 were 
higher than PLP which suggests poor binding into this isoform which is a desirable quality for 
useful inhibitors. A potential cause for these resultant docking scores may be the restricted 
rotation about the amide bond compared to an ester bond. Nonetheless, four amide inhibitors 
were chosen to be synthesized based off docking score and ease of synthesis. The top amide 
inhibitor was 3-(3,4,5-trihydroxybenzamido)phthalic acid (-7.434) which was near that of PLP. 
This amide utilized Asp129 for hydrogen bonding as did the β-amino acids and NSC107022; 
however, the hydrogen bonds were through the hydroxyl groups of the galloyl base (Fig. 14). 3-
(3,4,5-trihydroxybenzamido)phthalic acid also had π-π interactions with Tyr132 and the aromatic 
ring of the galloyl base. The hydroxyl group of the meta carboxylic acid hydrogen bonded to 
Trp49 and Arg53 while the ortho carboxylic group showed now significant interactions. 2-Nitro-
5-(3,4,5-trihydroxybenzamido)benzoic acid was oriented in the active site of LMW-PTP IF2 in a 
similar fashion to 3-(3,4,5-trihydroxybenzamido)phthalic acid. Hydrogen bonding was once 
again seen between Asp129 and the two of the galloyl hydroxyl group. Tyr132 also showed an 
interaction; however, this was a hydrogen bond to the last hydroxyl group of the galloyl base 
rather than a π-π interaction (Fig. 15). The remaining two amide inhibitors were not bound to 
LMW-PTP IF2 similarly to the previous two amides of β-amino acids (Figs. 11 and 12). 2-(4-
(3,4,5-trihydroxybenzamido)phenethyl)-1,4-phenylene diacetate did utilize Asp129 for hydrogen 
bonding through the nitrogen of the amide and one of the galloyl hydroxyl groups (Fig. 12).  
 3-Hydroxyphenyl 3,4,5-trihydroxybenzoate was the sole inhibitor chosen to be 
synthesized before in silico screening took place. This molecule was chosen based on its 
similarity to NSC107022 along with the added degrees of freedom. This was thought to give the 
inhibitor more freedom to situate itself in the active site; however, docking into LMW-PTP IF2 
resulted in a poor docking score (-6.276). Once again Asp129 and Tyr132 hydrogen bonded with 
the hydroxyl groups of the galloyl base as well as π-π interactions with the galloyl ring and 
Tyr132 (Fig. 4). Asp129 was utilized by all inhibitors to form hydrogen bonds with LMW-PTP 
IF2 and suggests it is an important residue in the inhibition of the enzyme. The amide inhibitors 
lacked interaction with Arg18 which was seen in all β-amino acid ester inhibitors, NSC107022 
and PLP. The poorer docking scores seen for the amide inhibitors may be due to the lacking of 
this interaction and also points to its importance in inhibition of LMW-PTP IF2. The added 
interactions of Cys17 and Ile16 for hydrogen bonding and Tyr131 for π-π interactions seen in the 
β-amino acid ester inhibitors suggests interaction with these residues result in tighter binding to 
LMW-PTP IF2. Structures and docking scores in LMW-PTP IF2 and IF1 for all chosen 
inhibitors can be seen in Table 1.  
 Original synthesis of the galloyl inhibitors involved the conversion of gallic acid to its 
acid chloride derivative and immediate coupling to either the aryl alcohol or aromatic amine. 
This resulted in the unwanted coupling between galloyl groups and was abandoned as a viable 
synthetic route. Starting from methyl gallate, synthesis of galloyl ester and amide inhibitors 
could be achieved in five steps with the exception of an extra step to prepare the β-amino acid 
coupling partners as adapted from previous literature and seen in Scheme 1.
15
 Following this  
 
Scheme 1.  
 
 
Reagents and conditions. BnBr, K2CO3, KI, acetone, reflux b) i. 6.0 M NaOH, reagent alcohol, reflux, ii. 0.6 M HCl, rt c) 
(COCl)2, toluene, 70
oC d) aryl alcohol/aromatic amine, DMAP, CH3CN, rt or reflux e) H2 atmosphere, toluene, 40
oC, X=O or 
NH. 
 
route, 3-hydroxyphenyl 3,4,5-trihydroxybenzoate was successfully synthesized which proved 
this to be a useful path towards synthesis of galloyl ester and amide inhibitors. 3-Hydroxyphenyl 
3,4,5-trihydroxybenzoate was then assayed in vitro  and fit to a competitive inhibition model to 
find its inhibition constant (Ki >> 500 µM). This first fully synthesized inhibitor showed very 
little inhibition in LMW-PTP IF2. Before synthesis of galloyl esters could continue the β-amino 
acid coupling partners had to be prepared from their aldehyde derivative. The β-amino acid motif 
has become more common in pharmaceutical products for its stability against protease hydrolysis 
and presence in many natural products.
16,17
 For this reason facile one-pot synthesis of β-amino 
acid derivatives have been developed.
17,18
 The synthetic route is outlined in Scheme 2. 3-Amino-
3-(3-hydroxyphenyl)propanoic acid was successfully synthesized following this route; however, 
the remaining β-amino acids were not able to be prepared. Presence of the hydroxyl group in the 
para position proved to donate electron density towards the aldehyde which reduced its 
electrophilicity nature and made it unable to participate in the desired reaction. Electron 
withdrawing groups, such as a simple acetate group and a trifluoro acetate group, were placed on  
 
Scheme 2.  
 
 
Reagents and conditions. a) NH4OAc, EtOH, reflux. 
 
the hydroxyl group to pull electron density away from the aldehyde. The presence of these 
groups did not result in successful synthesis of the β-amino acids due to the esters being cleaved 
under the given conditions resulting in a phenoxy anion. Literature reported products did not 
have strong electron donating groups in the para position
17,18
 and to the best of our knowledge 
only one β-amino acid with a hydroxyl group in the para position has been reported.19 To test if 
an electron withdrawing group in the para position could promote β-amino acid formation we 
started with 4-nitrobenzaldehyde and followed the conditions outlined in Scheme 2. This proved 
to be a successful route to synthesis the β-amino acids. Furthermore, to show that a phenoxy 
anion shuts down the reaction we started with 4-anisaldehyde and followed Scheme 2. The 
methoxy group proved to block penoxy anion formation and resulted in the β-amino acid. This 
leads us to believe future β-amino acids with a hydroxyl group in the para position could be 
synthesized through protection of the hydroxyl group with tert-butyldimethylsilyl ether 
(TBDMS), which is stable under the given conditions, and later cleaved under mild conditions to 
yield the final β-amino acid.  Both synthetic strategies proved successful and will allow us to 
form the desired β-amino acids followed by conversion of the nitro or TBDMS group to the 
necessary hydroxyl or amine group to yield the final β-amino acid coupling partner. Galloyl 
amide inhibitors were then prepared following Scheme 1. Two of the four chosen galloyl amide 
inhibitors have been crudely synthesized but have not been purified and hydrogenated to yield 
final inhibitors for in vitro evaluation.  
 
Conclusion 
The in silico screening of galloyl ester and amide inhibitors for human LMW-PTP IF2 yielded 
11 compounds for synthesis, seven esters and four amides, along with one ester prior to in silico 
screening. Asp129 was utilized by most inhibitors along with NSC107022 and PLP which 
suggests its importance in inhibition of LMW-PTP IF2. Arg18 was also seen interacting with all 
galloyl ester inhibitors, NSC107022 and PLP; however, this interaction was not seen in galloyl 
amide inhibitors which may have resulted in the poorer docking scores for the amides. 
Additional interactions with Cys17, Ile16 and Tyr131 seen in the β-amino acid motif of galloyl 
ester inhibitors may be important sites of intermolecular bonding which results in tighter binding 
to LMW-PTP IF2. The only fully synthesized inhibitor, 3-hydroxyphenyl 3,4,5-
trihydroxybenzoate, showed very little inhibition of LMW-PTP IF2 when assayed in vitro.  
 Further synthesis of galloyl amide inhibitors as well as a better process for synthesis of β-
amino acid coupling partners will result in more potential inhibitors of LMW-PTP IF2 and 
further optimization of NSC107022. Also, in vitro screening against LMW-PTP IF1 will 
determine inhibitor specificity for the two active isoforms of LMW-PTP and lead to new, 
specific inhibitors of LWM-PTP IF2. 
 
 
 
Fig. 2. PLP docked in LMW-PTP IF2 with key interactions shown.  
 
 
 
 
 
 
 
 
 
Fig. 3. Residue interactions of NSC107022 docked in LMW-PTP IF2. 
 
 
 
Fig. 4. 3-hydroxyphenyl 3,4,5-trihydroxybenzoate docked in LMW-PTP IF2 with key residue interactions 
shown. 
 
 
 
 
 
 
 
 
Fig. 5. 3-amino-3-(3-((3,4,5-trihydroxybenzoyl)oxy)phenyl)propanoic acid docked in LMW-PTP IF2 with key 
interactions shown. 
 
 
 
 
Fig. 6. 3-amino-3-(2-chloro-4-((3,4,5-trihydroxybenzoyl)oxy)phenyl)propanoic acid docked in LMW-PTP IF2 
with key interactions shown. 
 
 
 
 
 
 
 
 
 
 
Fig. 7.  3-amino-3-(3-methoxy-4-((3,4,5-trihydroxybenzoyl)oxy)phenyl)propanoic acid docked in LMW-PTP 
IF2 with key interactions shown.  
 
 
 
Fig. 8. 3-amino-3-(3-fluoro-4-((3,4,5-trihydroxybenzoyl)oxy)phenyl)propanoic acid docked in LMW-PTP IF2 
with key interactions shown. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 9. 3-amino-3-(3-nitro-4-((3,4,5-trihydroxybenzoyl)oxy)phenyl)propanoic acid docked in LMW-PTP IF2 
with key interactions shown. 
 
Fig. 10. 3-amino-3-(3-hydroxy-5-((3,4,5-trihydroxybenzoyl)oxy)phenyl)propanoic acid docked in LMW-PTP 
IF2 with key interactions shown.  
 
 
 
 
 
 
 
 
 
 
Fig. 11. 3-amino-3-(3,5-dimethyl-4-((3,4,5-trihydroxybenzoyl)oxy)phenyl)propanoic acid docked in LMW-
PTP IF2 with key interactions shown. 
 
Fig. 12. 2-(4-(3,4,5-trihydroxybenzamido)phenethyl)-1,4-phenylene diacetate docked in LMW-PTP IF2 with 
key interactions shown. 
 
 
 
 
 
 
 
Fig. 13. N-(5-(2-chlorophenyl)-1,3,4-oxadiazol-2-yl)-3,4,5-trihydroxybenzamide docked in LMW- 
PTP IF2 with key interactions shown. 
 
Fig. 14. 3-(3,4,5-trihydroxybenzamido)phthalic acid docked in LMW-PTP IF2 with key interactions shown. 
 
 
 
 
 
 
 
Fig. 15. 2-nitro-5-(3,4,5-trihydroxybenzamido)benzoic acid docked in LMW-PTP IF2 with key interactions 
shown. 
Table 1. Inhibitors structures and docking scores in LMW-PTP IF2 and IF1 along with PLP and NSC107022. 
Docking scores for NSC107022 obtained from Seiler et al.  
Molecule LMW-PTP IF2 LWM-PTP IF1 
 
-8.158 -7.625 
 
-8.787 -5.743 
 
-10.401 -11.343 
 
-10.332 -9.108 
 
-9.826 -6.292 
 
-9.790 -8.600 
 -9.667 -8.543 
 
-9.538 -8.383 
 
-9.397 -7.456 
 
-6.276 -6.069 
 
-7.434 -6.022 
 
-6.065 -3.435 
 
-5.568 -5.992 
 -5.258 -4.621 
 
 
Experimental 
 
Methyl 3,4,5-tribenzyloxybenzoate. A mixture of 186 mg (1 mmol) methyl 3,4,5-
trihydroxybenzoate, 795 mg (5.75 mmol) potassium carbonate and 33 mg (0.2 mmol) potassium 
iodide in 15 mL of dry acetone was stirred at room temperature for 20 min. At this time 380 µL 
(3.2 mmol) benzyl bromide in 1 mL of dry acetone was slowly added. The mixture was then 
heated to reflux for 18 h. At this time the reaction mixture was filtered, and the filtrated was 
evaporated to dryness then further dried under vacuum for 1 h to yield 425 mg (94%) 3,4,5-
tribenzyloxybenzoate as a white solid. 
1
H NMR (CD3COCD3) δ 3.83 (3H, s), 5.11 (2H, s), 5.20 
(4H, s) 7.25-7.50 (17H, m).  
 
3,4,5-Tribenzyloxybenzoic acid. 107 mg (0.24 mmol) methyl 3,4,5-tribenzyloxybenzoate was 
suspended in 10 mL reagent alcohol. 60 µL (0.35 mmol) 6M sodium hydroxide was added and 
mixture was heated to reflux for 2 h. The reaction mixture was then poured into 10 mL of hot 
0.6M hydrogen chloride and a white precipitate immediately forms which was stirred for 10 min. 
The precipitate was then filtered and washed successively with 2 mL 1:1 reagent alcohol/H20, 2 
mL H2O, 2 mL reagent alcohol, 2x1 mL methanol and 2x1 mL TBME. Resulting solid was then 
dried under vacuum for 3 h to yield 95 mg (91%) 3,4,5-tribenzyloxybenzoic acid as a white 
solid. 
1
H NMR (CD3COCD3) δ 5.11 (2H, s), 5.21 (4H, s), 7.24-7.50 (17H, m). 
 
3,4,5-Tribenzyloxybenzoyl chloride. 73 mg (0.17 mmol) 3,4,5-tribenzyloxybenzoic acid was 
suspended in 3 mL toluene and stirred at room temperature. 30 µL (0.33 mmol) oxalyl chloride 
in 1 mL toluene was added dropwise over 5 min and stirring at room temperature continued for 
20 min. The reaction mixture was then heated to 50 
o
C for 1 h. The mixture was then 
concentrated and taken up in 3 mL of toluene at 70
o
C and added to 3 mL cold cyclohexane. No 
precipitate was formed so the solution was evaporated to dryness and dried under vacuum for 1 h 
to yield 76 mg (97%) 3,4,5-tribenzyloxybenzoyl chloride as a light yellow solid. 
1
H NMR 
(CD3COCD3) δ 5.20 (2H, s), 5.26 (4H, s), 7.26-7.51 (17H, s). 
 
3-Hydroxyphenyl 3,4,5-tribenzyloxybenzoate. 65 mg (0.14 mmol) 3,4,5-tribenzyloxybenzoyl 
chloride, 65 mg (0.59 mmol) resorcinol and 16 mg (0.13 mmol) 4-dimethylaminopyridine were 
suspended in 3 mL acetonitrile and stirred at room temperature for 18 h. The reaction mixture 
was evaporated to dryness and purified on a silica column eluting with 65:35 hexanes/ethyl 
acetate to yield 33 mg (44%) 3-hyrdroxyphenyl 3,4,5-tribenzyloxybenzoate as a white solid. 
1
H 
NMR (CD3COCD3) δ 5.16 (2H, s), 5.25 (4H, s), 6.28 (1H, m), 6.71 (2H, m) 7.26-7.56 (18H, m), 
8.65 (1H, s). 
 
3-Hydroxyphenyl 3,4,5-trihydroxybenzoate. A suspension of 86 mg (0.16 mmol) 3-
hydroxyphenyl 3,4,5-tribenzyloxybenzoate and 38 mg (0.36 mmol) Pd/C was suspended in dry 
THF and stirred at 40
o
C under a positive atmosphere of hydrogen for 16 h. The reaction mixture 
was then cooled to room temperature and filtered through a thin layer of celite. The filtrated was 
evaporated to dryness and dried under a vacuum for 2 h to yield 40 mg (95%) 3-hydroxyphenyl 
3,4,5-trihydroxybenzoate as a gray semisolid. 
1
H NMR (CD3COCD3) δ 6.29 (1H, m), 6.69-6.75 
(2H, m), 7.22-7.24 (3H, m), 8.22 (1H, s) 8.39 (2H, s), 8.6 (1H, s). 
 
3-Amino-3-(3-hydroxyphenyl)propanoic acid. A mixture of 247 mg (2 mmol) 3-
hydroxybenzaldehyde and 313 mg (3 mmol) ammonium acetate in 5 mL ethanol was heated to 
reflux and stirred for 1 h. At this time 310 mg (4 mmol) malonic acid and an additional 
equivalent of ammonium acetate were added and refluxing continued for 3 h. A white precipitate 
formed in the reaction flask and was allowed to cool to room temperature before being placed on 
ice for one half hour. The precipitate was then filtered, washed with 2 x 1 mL ethanol and dried 
under reduced pressure for 1 h to yield 133 mg (37%) 3-amino-3-(3-hydroxyphenyl)propanoic 
acid as a white solid. 
1
H NMR (D2O) δ 2.63-2.75 (2H, m), 4.45 (1H, t), 6.78 (1H, m), 6.86 (2H, 
m), 7.24 (1H, M). 
 
3-Amino-3-(4-nitrophenyl)propanoic acid. A mixture of 100 mg (0.7 mmol) 4-
nitrobenzaldehyde, 91 mg (0.88 mmol) malonic acid and 108 mg (1.4 mmol) ammonium acetate 
in 5 mL ethanol was heated to reflux and stirred for 18 h. An off-white precipitate formed and 
was filtered and washed with 2 x 1 mL cool ethanol. The solid was collected and dried under 
reduced pressure to yield 60 mg (40%) 3-amino-3-(4-nitrophenyl)propanic acid as an off-white 
solid. 
1
H NMR (D2O) δ 2.73-2.86 (2H, m), 4.67 (1H, t), 7.63 (2H, d), 8.11 (2H, d). 
 
3-Amino-3-(4-methoxyphenyl)propanoic acid. A mixture of 95 mg (0.7 mmol) 4-
anisaldehyde, 91 mg (0.875 mmol) malonic acid and 108 mg (1.4 mmol) ammonium acetate in 5 
mL ethanol was heated to reflux and stirred for 18 h. A white precipitate formed and was 
filtered. Subsequent 2 x 1 mL washings with cool ethanol and drying under reduced pressure 
yielded 3-amino-3-(4-methoxyphenyl)propanoic acid as a white solid. Yield was not recorded. 
1
H NMR (D2O) δ 2.65-2.88 (2H, m), 3.74 (3H, s), 4.52 (1H, t), 6.96 (2H, d), 7.30 (2H, d). 
 
Supporting Information Experimental procedures for in silico methods and in vitro assay along 
with 
1
H NMR spectra for synthesized compounds can be found in the supporting information. 
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Supporting Information 
 
Molecular Modeling: 
 
Combinatorial Screening: A library of aromatic alcohols (approx. 3000 compounds) and the 
primary aromatic amine Selected Structure Set (approx. 3500 compounds) were obtained from 
Aldrich and were linked to the galloyl core for in silico screening using Maestro (Schrodinger, 
LLC.). 3,4,5-Tribenzyloxybenzoyl chloride was drawn and incorporated into Maestro  
workspace to be used as the coupling core. The core was then minimized and prepared using 
LigPrep with the MMFFs force field and a target pH of 5.5 ± 2.0. Compound libraries were then 
broken into smaller subsets and prepared using Reagent Preparation with the same target pH. 
The Amine_Primary_N_H functional group was selected and set to generate at most 10 
stereoisomers per compounds. Reagent prepared libraries and the galloyl core were then 
combined and docked into the 1XWW grid that was previously prepared using the Combinatorial 
Screening feature of Maestro. Once complete, compounds were analyzed and selected based on 
docking score with a more negative score being a better inhibitor. 
 
Individual Docking: After completion of combinatorial screening the top molecules were 
chosen based on docking score and ease of synthesis. These molecules were then docked 
individually into LMW-PTP IFB and IFA (1XWW and 5PNT, respectively) using the Glide 
docking feature of Maestro. The molecules were first drawn and incorporated into the Maestro 
work space. Minimization and ligand preparation were carried out as previously described. Once 
prepared the molecules were docked into either the 1XWW or 5PNT grids that were previously 
prepared using extra precision (XP) and flexible ligand sampling with the addition of Epik state 
penalties. The number of poses to report was set to 10 and performance of post-docking 
minimization was selected. Residue interaction scores were set for residues within 12.0 Å of the 
grid center. 
 
In vitro assay: 
 
Solution preparation: A 1.0 M acetic acid/sodium acetate buffer at pH 5.5 was prepared by 
dissolving 13.6 g sodium acetate in 100 mL of E-pure H2O and adding enough 1.0 M acetic acid 
(5.75 mL glacial acetic acid/100 mL E-pure H2O) to adjust the pH to desired value (approx. 15 
mL). 2.8 g of solid sodium hydroxide was added to 100 mL E-pure H2O to create a 0.5 sodium 
hydroxide solution used to quench the enzymatic reaction. P-nitrophenyl phosphate (pnpp) 
substrate was prepared as a stock 50 mM solution through the dissolving of 0.932 g of pnpp in 
50 mL E-pure H2O. The stock solution was diluted to sub-stock solutions of 10.0 mM, 5.0 mM, 
2.5 mM, 1.25 mM, 0.80 mM, 0.625 mM, 0.50 mM, 0.374 mM and 0.30 mM to be used in the 
enzyme assay. Inhibitors used in the assay were prepared by dissolving appropriate amount of 
inhibitor in H2O to create a 5 mM stock solution which was further diluted to 1 mM and 0.5 mM 
which were eventually used in the assay.   
 
In vitro assay: Reaction tubes were set up (Vfinal = 500 µL) containing 50 µL 1.0 M acetic 
acid/sodium acetate buffer, 100 µL of varying concentrations of sub-stock pnpp in the absence of  
inhibitor (330 µL E-pure H2O ) and 330 µL of two fixed concentrations of inhibitor (1 mM and 
0.5 mM). Inhibitor concentrations were determined as described previously.
4
 20 µL of enzyme 
(1:1 glycerol/enzyme solution diluted to give A405 = 0.12) was added to reaction tubes at 30 sec 
intervals and allowed to react for 15 min. At this time the reaction was quenched by removing 
100 µL from the reaction tube and addition to 150 µL 0.5 M KOH in a standard 96-well plate. 
Absorbance at 405 nm was then recorded and entered into a prepared spreadsheet to determine 
velocity of the reaction. The one substrate one inhibitor section of Visual Enzymics © of the 
IgorPro interface was used to determine the inhibition constant (Ki). Substrate and inhibitor 
concentrations (mM) were entered into the data sheet along with the velocity of the reaction. The 
standard deviation and mask was set to 1 for all reactions. The data was then fit to competitive, 
uncompetitive and mixed inhibition models.  
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